Date Headline Docs
20 Apr 2017 Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
19 Apr 2017 Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
06 Apr 2017 Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
05 Apr 2017 Targovax ASA: Protocol from the Annual General Meeting
04 Apr 2017 Targovax ASA: Proposal from the nomination committee to the annual general meeting 5 April 2017
23 Mar 2017 Targovax ASA moves share listing to Oslo Børs
15 Mar 2017 Targovax ASA: Notice of Annual General Meeting
15 Mar 2017 Targovax ASA: Annual Report 2016
06 Mar 2017 Targovax to present at upcoming conferences
16 Feb 2017 Targovax ASA: Fourth quarter and full year 2016 results
06 Feb 2017 Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February
02 Feb 2017 Targovax announces encouraging top line two-year survival data from TG01 clinical trial in resected pancreatic cancer patients
05 Jan 2017 Targovax announces appointment of Erik Digman Wiklund as CFO
Date Headline Docs
13 Dec 2016 Targovax to present at DNB healthcare conference
17 Nov 2016 Targovax ASA: Third quarter 2016 results
16 Nov 2016 Targovax to present at forthcoming conference
10 Nov 2016 Targovax granted European Patent for ONCOS platform lead product, ONCOS-102
08 Nov 2016 Targovax ASA: Invitation to third quarter 2016 results presentation Thursday 17 November
02 Nov 2016 Targovax announces appointment of Oystein Soug as CEO
21 Oct 2016 Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy
17 Oct 2016 Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium
19 Sep 2016 Targovax to present at Redeye's Fight Cancer conference
14 Sep 2016 Targovax to present at forthcoming conferences
25 Aug 2016 Targovax ASA: Interim Report second quarter and first half year 2016
15 Aug 2016 Targovax ASA: Invitation to second quarter 2016 results presentation Thursday 25 August
06 Jul 2016 Targovax presents encouraging preclinical data on ONCOS-102
12 May 2016 Targovax ASA: Interim report first quarter 2016
09 May 2016 Targovax to present at BioEquity Europe and its first quarter 2016 results on May 11 - 12, 2016
14 Apr 2016 Targovax reports immune response with reduced number of TG01 vaccinations
14 Mar 2016 Targovax to present at forthcoming Life Science and Investor conferences
10 Mar 2016 Targovax announces encouraging interim results with RAS specific peptide vaccine in resected pancreatic cancer
02 Mar 2016 Targovax ASA: Interim report fourth quarter 2015
Date Headline Docs
18 Nov 2015 Targovax ASA: LUDWIG CANCER RESEARCH AND CANCER RESEARCH INSTITUTE PARTNER WITH TARGOVAX TO TEST CANDIDATE VIROTHERAPY IN EARLY-PHASE CLINICAL TRIALS
14 Sep 2015 Targovax appoints two new directors to its board
03 Jul 2015 Targovax - Closing of the acquisition of Oncos Therapeutics Oy - PRESS RELEASE
11 Jun 2015 Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology - PRESS RELEASE
20 Apr 2015 Targovax ASA: Oncos Therapeutics presenting at the Anglonordic Life Science Conference on April 23rd in London, UK.
26 Feb 2015 Targovax ASA: Oncos represented at the 8th Annual Life Science CEO Forum & Exhibition March 3rd, 2015 in Zurich, Switzerland
26 Jan 2015 Targovax ASA: ONCOS-102 Mechanism of Action -video released on the website
12 Jan 2015 Targovax ASA: ONCOS-102 granted US lung cancer orphan drug designation
Date Headline Docs
17 Dec 2014 Targovax ASA: "ONCOS-102 sensitizes tumors to other immunotherapies" - Paper published in the latest issue of OncoImmunology
01 Dec 2014 Targovax awarded an immuno-oncology innovation prize
25 Nov 2014 Targovax ASA: Oncos Therapeutics receives a positive opinion on orphan drug designation for ONCOS-102
20 Nov 2014 Targovax ASA: Oncos presented a poster at EORTC-NCI-AACR Meeting 2014
10 Nov 2014 Targovax ASA: Oncos presented a poster at the SITC Annual Meeting 2014
05 Nov 2014 Targovax appoints Gunnar Gårdemyr as new CEO
05 Nov 2014 Targovax ASA: Sari Pesonen invited to present a poster at EORTC-NCI-AACR 2014, Nov 18-21, in Barcelona
05 Nov 2014 Targovax ASA: Frans Wuite invited to be a panelist in European Business Angel on Nov 17
03 Nov 2014 Targovax AS has reached an important milestone in the ongoing clinical trial investigating its cancer vaccine TG01 for treatment of operable pancreatic cancer.
30 Oct 2014 Targovax ASA: Frans Wuite presenting Oncos at Bio Europe 2014 on Nov 5, 2014 in Frankfurt
27 Oct 2014 Targovax ASA: Oncos presenting at the fall seminar of Statisticians in Finnish Pharmaceutical Industry held in Turku, Finland Oct 30, 2014
08 Oct 2014 Targovax ASA: Oncos presented a poster entitled "Intratumoral ONCOS-102 Shapes the Tumor Microenvironment in Last-Line Refractory Solid Tumor Patients"
11 Sep 2014 New member of the Board
16 Jun 2014 Targovax AS is registered on the NOTC-list
04 Jun 2014 Targovax successfully completes a 70 MNOK financing
04 Jun 2014 Targovax ASA: Oncos Therapeutics recruits Dr Magnus Jaderberg as CMO to strengthen its focus on cancer immunotherapy - PRESS RELEASE
02 Jun 2014 Oncos Therapeutics granted US and EU Orphan Drug Designation for ONCOS-102 in ovarian cancer - PRESS RELEASE
08 May 2014 Targovax ASA: ONCOS - achievement in cancer immunotherapy - PRESS RELEASE
04 Apr 2014 Targovax in Dagens Medisin
28 Feb 2014 Targovax ASA: ATMP classification for ONCOS-102 by European Medicines Agency
06 Feb 2014 Targovax TG01 immunotherapy reaches phase IIA in operable pancreatic cancer
31 Jan 2014 Targovax ASA: Oncos Therapeutics among Top 20 Finnish startup companies by Talouselämä journal